PharmiWeb.com - Global Pharma News & Resources

Biotech - Press Releases

Date Title Company
09-May-2022 Alfa Chemistry: Photochromic Materials Exhibit Intriguing Optical Properties Alfa Chemistry
05-May-2022 Immutep presents new and significant data from the AIPAC study Immutep
05-May-2022 Applications open for SmiLe’s international Biotech program with BioM and Merck SmiLe Incubator
05-May-2022 CD Formulation Enriches Its Supply of Active Pharmaceutical Ingredient Excipients CD Formulation
05-May-2022 Novotech Acquires US CRO NCGS, Expands Global Expertise Novotech Health Holdings Pte Ltd
04-May-2022 New Data Opens Potential for Patient Stratification for CriPec® Nanomedicines in Cancer and Other Indications via Non-Invasive Imaging Cristal Therapeutics
04-May-2022 New Data Opens Potential for Patient Stratification for CriPec® Nanomedicines in Cancer and Other Indications via Non-Invasive Imaging Cristal Therapeutics
04-May-2022 Foundation S: Sanofi’s new philanthropic spearhead Sanofi
04-May-2022 BioWin spearheads ‘Talent Now’, a unique initiative to tackle recruitment shortages and challenges in the healthtech industry Andrew Lloyd Associates
04-May-2022 Seung Jae Lee, CEO of C&L Therapeutics - I Chose to Collaborate to Create a Luxury New Drug Jubilant Biosys
03-May-2022 Orgenesis Led Consortium awarded EUR 4M European Innovation Council Pathfinder Grant Orgenesis
03-May-2022 JYSELECA®▼ (filgotinib), recommended by the Health Service Executive (HSE) for people with Ulcerative Colitis (UC) in Ireland Galapagos Biotech
03-May-2022 Solvay launches new growth platform focused on renewable materials and biotechnology Solvay
03-May-2022 Engimmune Therapeutics raises CHF 15.5 million in seed financing to develop novel T-cell receptor therapeutics Engimmune Therapeutics
03-May-2022 STORM Therapeutics Awarded Innovate UK Grant to Discover and Develop a Novel Coronavirus Therapy Targeting an RNA-Modifying Enzyme STORM Therapeutics
03-May-2022 Biomunex unveils MAIT cell redirection approach for lead immune-oncology program at PEGS Boston Conference Andrew Lloyd Associates
03-May-2022 JYSELECA®▼ (filgotinib), recommended by the Health Service Executive (HSE) for people with Ulcerative Colitis (UC) in Ireland Galapagos Biotech LTD
03-May-2022 AdBio partners welcomes Inserm Transfert as investor in second fund – AFB Fund II Andrew Lloyd Associates
03-May-2022 Isorg appoints Dieter May as new CEO Andrew Lloyd Associates
29-Apr-2022 Accelerating Peptide Drug Research with Creative Peptides’ Premade Peptide Library Creative Peptides